Results for HLD-0915 Demonstrate Encouraging Safety and Anti-Tumor Activity in Metastatic CRPC

“These preliminary results suggest that HLD-0915, an oral, once daily therapy, can achieve meaningful anti-tumor activity with a clean safety profile in mCRPC patients who had failed up to 8 prior mCRPC therapies,” said Dr. Andrew Hahn, Assistant Professor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, who presented the HLD-0915 data in the oral plenary session. “Furthermore, HLD-0915 demonstrated clinical activity regardless of genomic heterogeneity – including androgen receptor (AR) mutations, splice variants or amplifications. Given the limited treatment options for mCRPC patients, these clinical findings support the differentiated approach to drive a precision cell-killing effect through a novel mechanism that does not rely on cancer drivers that can cause drug resistance.”